Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

icient method for producing Id/KLH immunotherapies, but also the added advantage of making them potentially more active as well."

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan(R) induction therapy in patients with follicular B-cell NHL in January 2006. Analysis of the primary endpoint, time to disease progression, is event driven and currently projected to occur during the fourth quarter of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/2/2008)...if., Dec. 2 TorreyPines Therapeuti...e results from a 26 patient Phase II trial evaluat...tomia, or dry mouth, in patients with Sjogren,s sy...istically significant increase in salivary flow pr...0 mg, 15 mg, and 20 mg. These doses were safe and ...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/2/2008)..., Dec. 2 Micromet, Inc. ...eloping novel, proprietary antibodies for the trea...ses, today announced that it has entered into an a...Facility (CEFF) with Kingsbridge Capital Limited, ...e agreement, Kingsbridge has committed to provide ...
(Date:12/1/2008)... 2 New research has fou... computed tomography (CT) scanner in an emergency ...ke victims who receive a potentially life-saving t... Shore Medical Center (NSMC)-Salem Hospital in Sal...eeting of the Radiological Society of North Americ...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3NCPA Applauds U S House Vote in Favor of H R 6331 22698 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 2New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 3New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 4New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 5New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 6New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 7New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 8New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 9Drug Coated Stents Reduce Repeat Artery Procedures 22693 1Drug Coated Stents Reduce Repeat Artery Procedures 22693 2Drug Coated Stents Reduce Repeat Artery Procedures 22693 3Certain anti cancer agents could be harmful to patients with heart disease 22689 1Certain anti cancer agents could be harmful to patients with heart disease 22689 2Certain anti cancer agents could be harmful to patients with heart disease 22689 3
...ON VALLEY, Pa.--(BUSINESS WIRE)--Apr 12, 2007 - Im...at the American,Association for Cancer Research (A...5 to 18. The Company will feature,Immunicon Pharma...at Kit and the new EasyCount(TM) System at booth 1...opment and clinical,trial testing services to some...
...c found to dramatically reduce the risk of cancer,...estinal stromal,tumors (GIST) , * Patients receivi...c , * Global regulatory submissions planned for us...ollowing surgery to remove,primary tumor , * Glive...ts with,advanced metastatic or inoperable Kit-posi...
Other Medicine Technology:Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:12/2/2008)...SANTA BARBARA, Calif., Dec. 2 Bio...g products and services, and Alere(R) , who provi..., productivity improvement and complex care manage...trophic conditions to health plans, employers, and... BioIQ,s home-test kits and online reporting tools...
(Date:12/2/2008)...LONDON, Dec. 2 Services form an in...turers, (OEMs,) revenues. It has therefore become,...edical imaging services,market to remain competit...tract penetration rates. , (Logo: http://... New analysis from Frost & Sullivan ( htt...
(Date:12/2/2008)... SPEAK to collect and dis... Bellevue, Wash. (PRWEB) Dece...nnounced the launch of a new initiative to focus p... awareness . The official kick-off of SPEAK will o...Pharmacists (ASHP) 2008 Midyear Clinical Meeting, ...
(Date:12/2/2008)... Xena Health and Solution...l Claims Service "Claims in a Cloud" as ...sgow and London (PRWEB) December 2, 2008 -- Making...s to the launch of the first phase of a "Cl... solution from Corporate Modelling partners Xena ...
Breaking Medicine News(10 mins):Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 3Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:Corporate Modelling Partners Start Selling BPM in Cloud Service 2
...holesterol can do to people. High-fat diets cause ...re looking at food labels // to know what they con... easier for consumers to avoid trans fats, which p...ked to an increased risk of heart disease, among o...
...e a greater risk of developing Alzheimer’s, the de...stralian researchers // has claimed. The researc...delphia and the Edith Cowan University in Western ...e 'almost certainly' increases risk from Alzheimer...
...y among the people of Queensland when it comes to ...okesman for Queensland Institute of Medical Resear...drive against skin cancer is not having the desire...MR did not elicit the expected number of responses...
...nd are seeking legal protection in the event of a ...n they would be compelled to work // under adverse...ety (OSH) regulations in force in the country are ... sued as per the law. This is very much likely w...
Other Medicine News:Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
...iciency and quality to routine urine microscopic a...luorescent flow cytometry with fully automated uri...processing are easily accommodated by the rack-bas... high volume laboratories. Fluorescent flow cytom...
... is a single-use, disposable needle loading device... a Bard BrachyStar needle for interstitial seed im...on safety shield, inner compartment that holds see...lded fitting that connects the cartridge to the ne...
...System uses technology developed by Mortara, the c... digital Holter recorder in 1994. This true 12-lea...r study provides superior ST segment analysis. ,...l recorder allows a full 24-hour 12-lead study to ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems
Medicine Products: